Valeriana Cesarini earned her Master’s degree in Medical Biotechnology from the Catholic University of Rome in 2011 and completed her PhD in 2015 within the PhD programme in Biotechnologies and Translational Medicine at Tor Vergata University of Rome. She carried out her postdoctoral research at the Bambino Gesù Pediatric Hospital in Rome, where she developed her expertise in the field of RNA modifications.
In 2020, she obtained a tenured researcher position at the Institute of Translational Pharmacology of the National Research Council (IFT-CNR) and in 2025, she joined the Milan Unit of the Institute of Genetic and Biomedical Research (IRGB-CNR) to work in Dr. Catalucci’s group.
Dr. Cesarini’s research focuses on the role of the post-transcriptional mechanism known as A-to-I RNA editing in heart failure. Her work aims to identify RNA editing events that characterize altered cardiac tissue and to explore innovative strategies to modulate these events, potentially opening new therapeutic avenues for heart failure.